Replimune Cuts Quarterly Loss To $57.1 Million As Tudriqev Reaches Patients
The melanoma drug maker says it holds over a year of inventory and cash to fund operations for more than twelve months.
Replimune, the Woburn, Massachusetts biotech whose engineered-virus therapy Tudriqev for advanced melanoma first reached patients on October 6, reported a net loss of $57.1 million, or $0.54 per share, for its fiscal second quarter ended September 30. A year earlier the loss was $83.1 million, or $0.90 per share, the company said Wednesday.
Spending falls on both lines
Research and development costs dropped to $34.4 million from $57.9 million a year earlier. The company attributed that mainly to lower personnel and other costs, plus reduced direct research spending on its IGNYTE, ARTACUS and CERPASS studies.
Selling, general and administrative costs fell to $21.9 million from $26.4 million. Stock-based compensation was $4.9 million of the research line and $5.7 million of the administrative line.
For the first six months of the fiscal year, the net loss was $126.9 million, or $1.26 per share, against $169.8 million, or $1.85 per share, a year before.
Tudriqev's first weeks on the market
Replimune is a commercial-stage company developing oncolytic immunotherapies, which use an engineered herpes simplex virus to kill tumors and prompt an immune attack. Tudriqev, previously called RP1, is approved for use with nivolumab in adults with advanced melanoma that progressed after a PD-1-blocking therapy. The approval is accelerated, and continued approval may depend on a confirmatory trial.
More than 15 institutions have prescribed the drug, the company said. It has actively engaged more than 70% of its initial 200 priority accounts to set up workflows, and says it has more than a year of inventory made at its in-house plant. Multiple payer policies now cover the drug to label, and it is listed in the NCCN oncology guidelines as a category 2A recommendation.
"Melanoma takes nearly 8,500 lives in the U.S. every year," CEO Sushil Patel said, adding that physicians value the broad label that lets them treat patients right after progression on a PD-1 based therapy.
Cash and the confirmatory trial
Cash and cash equivalents were $307.8 million on September 30, against $268.9 million in cash and short-term investments at March 31. The company cited about $141.0 million in net proceeds from an August offering of stock and pre-funded warrants, and $15.0 million from an initial draw on a debt tranche in September, partly offset by operating cash burn.
Management expects the cash to fund operations, including the Tudriqev launch, for more than twelve months from the issuance of the financial statements.
The global IGNYTE-3 Phase 3 trial, the confirmatory study, is actively enrolling, with overall survival as the primary goal. A separate registration-directed trial of RP2 in metastatic uveal melanoma, called REVEAL, is also enrolling.
The IGNYTE-3 trial, with overall survival as its main goal, is the study that will verify the clinical benefit on which Tudriqev's continued approval may depend.
Sources
- 8-K Filing — Replimune Group, Inc. (REPL) — SEC EDGAR
- Exhibit tm2628395d1_ex99-1.htm — Replimune Group, Inc. 8-K exhibit — SEC EDGAR
- Replimune Reports Fiscal Second Quarter 2027 Financial — globenewswire.com
- Replimune to Report the Fiscal Second Quarter 2027 — globenewswire.com